Lv1
10 积分 2021-07-06 加入
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment
2小时前
已完结
Understanding and managing the possible adverse effects associated with bevacizumab
20天前
已完结
Spontaneously ruptured hepatocellular carcinoma on non-cirrhotic liver: A prospective case series
22天前
已关闭
Phase 2 Evaluation of Neoadjuvant Intensity-Modulated Radiotherapy in Centrally Located Hepatocellular Carcinoma
1个月前
已完结
Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial
1个月前
已完结
BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update
3个月前
已完结
Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: A multi-center cohort study
4个月前
已完结
皖公网安备34019202002308
